A022101 : A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASUR), (NCT TBD)
Principal Investigator
Study Number
STUDY02001917
Summary
A022101 study is for patients who have advanced colorectal cancer that has spread up to four body sites. This study will compare standard treatment to standard treatment with the addition of ablative local therapy (ALT). It is common to use ALT. However, it is not scientifically proven that the addition of ALT is beneficial for your stage of cancer. This study is hoping to be prove if it is beneficial or not. ALT may be performed by surgery, radiation therapy or heat with microwave ablation. Patients will be assigned randomly to one of two groups: about 200 people will be treated with standard treatment and about 200 will be treated with standard treatment with ALT. People who take part in this study will receive study treatment until cancer progression, after they will be followed by the study team for 4-5 years after completing treatment.
Phase
III
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms